Thoratec
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Thoratec's revenues will drop -3.3% and EPS will wither -7.8%.
The average estimate for revenue is $122.6 million. On the bottom line, the average EPS estimate is $0.47.
Revenue details
Last quarter, Thoratec reported revenue of $128.5 million. GAAP reported sales were 17% higher than the prior-year quarter's $109.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $0.38. GAAP EPS were -$0.25 for Q4 versus $0.25 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 69.7%, 70 basis points worse than the prior-year quarter. Operating margin was 19.7%, 650 basis points worse than the prior-year quarter. Net margin was -11.2%, much worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $503.9 million. The average EPS estimate is $1.83.
Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 150 members out of 172 rating the stock outperform, and 22 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Thoratec a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thoratec is outperform, with an average price target of $40.13.
Is Thoratec the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Thoratec to My Watchlist.
